Medindia

DaTscan™ (Ioflupane I 123 Injection) Now Available to Help Physicians Assess Patients with Suspected Parkinsonian Syndromes

PRINCETON, N.J., June 28, 2011 /PRNewswire/ -- GE Healthcare today announced the availability of DaTscan™ (Ioflupane I 123 Injection), in more than 80 hospitals across the US. DaTscan is the first FDA ...
News Medical

DaTscan allows doctors to differentiate Parkinson's from other movement disorders

Thanks to a new diagnostic imaging technique, physicians now have an objective test to evaluate patients for parkinsonian syndromes, such as Parkinson's disease. Northwestern Memorial Hospital is ...
Business Wire

DaTSCAN™ (Ioflupane I 123 Injection) SPECT Imaging Impacts the Diagnosis and Clinical Management of Patients with Clinically Uncertain Parkinsonian Syndrome

DUBLIN--(BUSINESS WIRE)--GE Healthcare today presented the results of a randomised controlled study analyzing the effect of DaTSCAN™ (Ioflupane I 123 Injection) SPECT imaging in a group of adult ...
The Globe and Mail

DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB)

GE Healthcare’s DaTscan has been approved by the U.S. Food and Drug Administration (FDA) for use in patients with suspected Dementia with Lewy Bodies (DLB). This new indication is in addition to its ...
Monthly Prescribing Reference

DaTscan radiopharmaceutical agent approved for detection of dopamine transporters

The FDA has approved DaTscan (Ioflupane I 123 Injection, from GE Healthcare) for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters (DaT) ...
Medscape

FDA Approves DaTscan for Imaging of Dopamine Transporters

January 17, 2011 — GE Healthcare has announced Food and Drug Administration (FDA) approval of ioflupane iodine-123 injection (DaTscan), a contrast agent for use with single-photon emission computed ...
Monthly Prescribing Reference

DaTSCAN Aids Diagnosis of Dementia with Lewy Bodies

DaTscan (ioflupane I 123 injection; GE Healthcare) was found to improve a physician’s ability to definitively diagnose patients with dementia with Lewy bodies (DLB) and increase their confidence in ...
WAVY-TV

SimonMed Announces offering of DaTscan

SCOTTSDALE, Ariz., April 24, 2023 /PRNewswire/ -- SimonMed is proud to announce we will offer GE HealthCare's radiopharmaceutical diagnostic tracer, DaTscan™ (Ioflupane I 123 injection), with ...
Business Wire

GE Healthcare: DaTscan™ (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis and Clinical Management of Patients with Clinically Uncertain ...

DaTscan is a radiopharmaceutical imaging agent that works by binding to dopamine transporters (DaT) in the brain. A specific marker for DaT, DaTscan produces images that provide visual evidence based ...
elEconomista

DaTSCAN TM (Ioflupane I 123 Injection) SPECT Imaging Demonstrates Impact on the Diagnosis of Patients with Clinically Uncertain Dementia with Lewy Bodies

GE Healthcare today presented the results of a randomized study analyzing the effect of DaTSCAN TM (Ioflupane I 123 Injection) SPECT imaging in a group of adult patients with a diagnosis of possible ...
PharmiWeb

DATSCAN™ (Ioflupane I 123 Injection) indication expanded to include use in patients with suspected Dementia with Lewy Bodies (DLB)

DaTscan is first radiopharmaceutical diagnostic tracer approved by U.S. FDA for use in patients with suspected Dementia with Lewy Bodies (DLB) Builds on DaTscan market leadership globally with over ...